GALT
Price
$3.80
Change
-$0.08 (-2.06%)
Updated
Oct 1, 01:50 PM (EDT)
Capitalization
396.34M
46 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$7.31
Change
+$0.10 (+1.39%)
Updated
Oct 1, 01:50 PM (EDT)
Capitalization
218.14M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GALT vs RNAC

GALT vs RNAC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GALT vs. RNAC commentary
Oct 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GALT is a Hold and RNAC is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
GALT vs RNAC: Fundamental Ratings
GALT
RNAC
OUTLOOK RATING
1..100
8764
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4665
P/E GROWTH RATING
1..100
10033
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GALT's Valuation (92) in the Biotechnology industry is in the same range as RNAC (98). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

GALT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

GALT's SMR Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

GALT's Price Growth Rating (46) in the Biotechnology industry is in the same range as RNAC (65). This means that GALT’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (33) in the Biotechnology industry is significantly better than the same rating for GALT (100). This means that RNAC’s stock grew significantly faster than GALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GALTRNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 28 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 01, 2026
Stock price -- (GALT: $3.88 vs. RNAC: $7.21)
Brand notoriety: GALT and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GALT: 59% vs. RNAC: 155%
Market capitalization -- GALT: $396.34M vs. RNAC: $218.14M
GALT [@Biotechnology] is valued at $396.34M. RNAC’s [@Biotechnology] market capitalization is $218.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GALT’s FA Score shows that 0 FA rating(s) are green while RNAC’s FA Score has 1 green FA rating(s).

  • GALT’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 1 green, 4 red.
According to our system of comparison, RNAC is a better buy in the long-term than GALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GALT’s TA Score shows that 6 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • GALT’s TA Score: 6 bullish, 4 bearish.
  • RNAC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GALT is a better buy in the short-term than RNAC.

Price Growth

GALT (@Biotechnology) experienced а -4.20% price change this week, while RNAC (@Biotechnology) price change was -8.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.19%. For the same industry, the average monthly price growth was -11.77%, and the average quarterly price growth was -0.24%.

Reported Earning Dates

GALT is expected to report earnings on Nov 16, 2026.

RNAC is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GALT
Daily Signal:
Gain/Loss:
RNAC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NA2.210.04
+1.84%
Nano Labs Ltd
KBONU10.30N/A
N/A
Karbon Capital Partners Corp
NBHC39.19-0.04
-0.10%
NATIONAL BANK HOLDINGS Corp
TSBK44.58-0.30
-0.67%
Timberland Bancorp
TGTX55.78-0.41
-0.73%
TG Therapeutics